Los Angeles Capital Management
LEGN icon

Los Angeles Capital Management’s Legend Biotech LEGN Stock Holding History

Los Angeles Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-161,780
Closed -$5.49M – 1408
2025
Q1 		$5.49M Sell
161,780
-10,660
-6% -$382K 0.02% 280
2024
Q4 		$5.61M Buy
+172,440
New +$7.14M 0.02% 312
2023
Q1 		– Sell
-6,351
Closed -$317K – 1235
2022
Q4 		$317K Sell
6,351
-2,736
-30% -$133K ﹤0.01% 1022
2022
Q3 		$371K Hold
9,087
– – ﹤0.01% 1012
2022
Q2 		$500K Hold
9,087
– – ﹤0.01% 965
2022
Q1 		$330K Buy
+9,087
New +$359K ﹤0.01% 1210

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Los Angeles Capital Management's LEGN Position: Q2 2025 in Review

Los Angeles Capital Management sold out of Legend Biotech (LEGN) in Q2 2025, closing a stake of 161,780 shares — an estimated $5.49M sold.

Los Angeles Capital Management first reported a position in LEGN in Q1 2022 and held it in 6 quarters. The position peaked at $5.61M in Q4 2024. 211 funds tracked by Wall St. Rank hold LEGN as of Q2 2025.

  • Los Angeles Capital Management reported no remaining Legend Biotech position as of Q2 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 161,780 Legend Biotech shares in Q2 2025, an estimated $5.49M.
  • Los Angeles Capital Management first reported a position in Legend Biotech in Q1 2022 and held it in 6 quarters.
  • Los Angeles Capital Management's Legend Biotech position peaked at $5.61M in Q4 2024.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2025.

Based on Los Angeles Capital Management's 13F filing for Q2 2025, filed 7 Aug 2025.